Taiho Pharmaceutical Company Limited

Kazutaka Miyadera

Yuji Yamada

Takeshi Sagara

Hiroki Irie

Yuichi Kawai

Konstanty Wierzba

Tomohiro Emura

Yuji Takebayashi

Shinichi Hasako

Shinichi Akiyama

Yoshimi Aoyagi

An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.

Selective inhibitor of exon 20 insertion mutant EGFR

To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 inhibitory effect. The present invention provides a compound of formula (I) wherein X, Y, Z, Z, Z, Z, W, n, R, R, and Rhave meanings as defined in the present specification, or a salt thereof. 

Pyrazolo[3,4-d]pyrimidine compound or salt thereof

This invention provides a drug which has inhibitory activities against thymidine phosphorylase and inhibits metastasis of a cancer. Specifically, this invention relates to a cancerous metastasis inhibitor comprising, as an active ingredient, a uracil derivative represented by the following formula (1):

Cancerous metastasis inhibitors containing uracil derivatives

Monoclonal antibodies

Growing community of inventors

Chiyoda-ku, Japan

Kazutaka Miyadera